View Exam | PowerPak

1. For patients who have persistent symptoms and frequent exacerbations, which of the following does not need to be completed prior to therapy intensification?

A. Check inhaler technique B. Assure strict medication adherence C. Recommend the addition of inhaled tiotropium to the provider D. Inquire about potential allergen exposure and counsel on the avoidance of triggers E. Unsure

2. Which of the following asthma therapies is a monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling?

A. Dupilumab B. Reslizumab C. Mepolizumab D. Benralizumab E. Unsure

3. Which of the following is NOT a contributing factor to a successful patient-reported outcomes program in the management of asthma?

A. Patient agreement to treatment strategies and therapy goal achievement B. An established relationship between the patient and the healthcare provider C. Patient willingness to self-report asthma symptoms periodically D. Patient knowledge about asthma drug costs E. Unsure

4. Which of the following patient-reported measures is considered by both the Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention 2020 Report (GINA 2020) and the Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma (EPR-3) to best assess a patient's overall level of asthma management?

A. Frequency of prescribed oral corticosteroids in the previous 3 months B. Quality of life C. Symptom control D. Laboratory tests, such as absolute eosinophil count or serum immunoglobulin E E. Unsure

5. Which of the following patient-reported outcome measurement tools has not yet been recommended in the treatment guidelines for use in clinical practice to guide clinical decisions?

A. Asthma Control Test (ACT) B. Mini Asthma Quality of Life Questionnaire (miniAQLQ) C. Asthma Control Questionnaire (ACT) D. Asthma Therapy Assessment Questionnaire (ATAQ) E. Unsure

6. Which of the following statements is FALSE regarding shared decision-making?

A. Patients who actively participate in the decision-making process have higher patient satisfaction scores B. Patients who actively participate in the decision-making process are less likely to open up to their providers about treatment-related issues C. Patients who actively participate in the decision-making process have improved adherence D. Patients who actively participate in the decision-making process have better asthma symptom control E. Unsure

7. Which of the following statements is outside of the pharmacist's scope in improving patient-reported outcomes?

A. Identify barriers to adherence and counsel on ways to overcome them B. Prescribe an add-on treatment, such as montelukast, to the patient's current medication regimen C. Gauge patient's readiness to quit smoking and provide counseling if she is ready to quit D. Review and ensure proper inhaler technique E. Unsure

8. Which of the following comorbid conditions does NOT have a significant impact on asthma?

A. Hypertension B. Seasonal allergic rhinitis C. GERD D. Depression E. Unsure

9. CC agrees to a consultation with you; she demonstrates her inhaler technique, which you deem as satisfactory. When asked about her written asthma plan, CC states she does not have one and is unsure of what you're asking her about. What is the purpose of a written asthma plan?

A. It allows patients to record daily peak flow measurement results and share them with their provider B. It makes recommendations to patients about how to manage daily asthma symptoms, such as when to use the prescribed reliever medication and when to seek medical attention C. It serves as a medication list for patients with asthma D. It lists a patient's common environmental triggers and how to avoid them E. Unsure

10. You ask CC about her social history. She tells you she is not interested in quitting smoking. Which of the following would be an appropriate response to CC's unwillingness to quit smoking?

A. Confront her about the dangers and risks of continued cigarette use in patients with asthma B. Recommend a nicotine replacement product that requires frequent administration C. Use motivational interviewing techniques to identify why CC is reluctant to quit smoking D. Simply do nothing; CC will decide to quit only when she is ready E. Unsure

Evaluation Questions

11. How confident are in your treatment choices for the CC?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. For patients who have persistent symptoms and frequent exacerbations, which of the following does not need to be completed prior to therapy intensification?

2. Which of the following asthma therapies is a monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling?

3. Which of the following is NOT a contributing factor to a successful patient-reported outcomes program in the management of asthma?

5. Which of the following patient-reported outcome measurement tools has not yet been recommended in the treatment guidelines for use in clinical practice to guide clinical decisions?

6. Which of the following statements is FALSE regarding shared decision-making?

7. Which of the following statements is outside of the pharmacist's scope in improving patient-reported outcomes?

8. Which of the following comorbid conditions does NOT have a significant impact on asthma?

9. CC agrees to a consultation with you; she demonstrates her inhaler technique, which you deem as satisfactory. When asked about her written asthma plan, CC states she does not have one and is unsure of what you're asking her about. What is the purpose of a written asthma plan?

10. You ask CC about her social history. She tells you she is not interested in quitting smoking. Which of the following would be an appropriate response to CC's unwillingness to quit smoking?

Evaluation Questions

11. How confident are in your treatment choices for the CC?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. For patients who have persistent symptoms and frequent exacerbations, which of the following does not need to be completed prior to therapy intensification?

2. Which of the following asthma therapies is a monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling?

3. Which of the following is NOT a contributing factor to a successful patient-reported outcomes program in the management of asthma?

5. Which of the following patient-reported outcome measurement tools has not yet been recommended in the treatment guidelines for use in clinical practice to guide clinical decisions?

6. Which of the following statements is FALSE regarding shared decision-making?

7. Which of the following statements is outside of the pharmacist's scope in improving patient-reported outcomes?

8. Which of the following comorbid conditions does NOT have a significant impact on asthma?

9. CC agrees to a consultation with you; she demonstrates her inhaler technique, which you deem as satisfactory. When asked about her written asthma plan, CC states she does not have one and is unsure of what you're asking her about. What is the purpose of a written asthma plan?

10. You ask CC about her social history. She tells you she is not interested in quitting smoking. Which of the following would be an appropriate response to CC's unwillingness to quit smoking?

Evaluation Questions

11. How confident are in your treatment choices for the CC?

« Return to Activity

Customers who Purchased
this Activity also Purchased